-- Robert Preidt
FRIDAY, Oct. 25 (HealthDay News) -- The use of a hands-free
ultrasound device in combination with a clot-busting drug appears
safe for patients with a common kind of stroke, a small, new study
An ischemic stroke occurs when blood flow to the brain is
blocked. When this happens, the hands-free ultrasound device is
placed on the patient's head and delivers ultrasound to boost the
effectiveness of the clot-busting medicine tPA (tissue plasminogen
The new trial was funded by the U.S. National Institutes of
Health and was published Oct. 24 in the journal
"Our goal is to open up more arteries in the brain and help stroke patients recover," study author Dr. Andrew Barreto, an assistant professor of neurology in the Stroke Program at the University of Texas Health Science Center at Houston, said in a journal news release.
Unlike the traditional hand-held ultrasound device that's aimed
at a blood clot, the hands-free version uses 18 separate probes and
showers the deep areas of the brain where large blood clots cause
severe strokes, the researchers said.
The new study included 12 men and eight women with an average
age of 63. The patients had moderately severe ischemic strokes and
received tPA within four and a half hours after the start of their
stroke symptoms. They also received two hours of exposure to the
hands-free ultrasound device.
Ninety days after the combined treatment, 65 percent of the
patients had either returned home or were in post-stroke
rehabilitation. A quarter of the patients had no stroke-related
disability, and one patient had slight disability.
"This technology would have a significant impact on patients, families and society if we could improve outcomes by another 5 percent to 10 percent by adding ultrasound to patients who've already received tPA," Barreto said.
Barreto's team has launched an international study of the
ultrasound approach combined with the clot buster, to be conducted
in 830 ischemic stroke patients.
Two stroke experts not connected to the study said the device
"The potential benefit of this technology is its simplicity and potential for widespread use within primary stroke centers that are the first to see the majority of ischemic stroke patients," said Dr. Jeffrey Katz, chief of vascular neurology at North Shore University Hospital in Manhasset, N.Y.
Katz said that if the data from trials continues to be positive,
"we may finally have the first proven adjunct to intravenous tPA
that has the potential for mass use because it does not rely on the
availability of trained operators or expensive specialized
Dr. Sampson Davis, an emergency medicine physician at St.
Michael's Medical Center in Newark, N.J., added: "Because I am the
first doctor to encounter stroke patients, I'm excited about
medical technology and thrilled to see such a timely study
"Although more research steps are needed, including the aforementioned larger patient size, this project holds promise and is a step in the right direction in treating stroke," Davis said.
The U.S. National Institute of Neurological Disorders and Stroke
has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.